Objective: It remains controversial whether non-malignant 'benign' hypertension causes renal dysfunction. The effect of lowering blood pressure on the incidence of renal dysfunction among patients with non-malignant hypertension is not clear. This meta-analysis was conducted to determine whether antihypertensive drug therapy reduces the incidence of renal dysfunction in patients with non-malignant hypertension. Methods: Randomised, controlled trials of antihypertensive drug therapy of more than 1 year duration that reported renal dysfunction as an outcome were identified through MEDLINE search and literature review. A random effects model was used to obtain summary estimates. Results: Ten trials were identified, involving 26 521 individuals and 114 000 person-years. All excluded subjects with advanced baseline renal disease. Definition of renal
Introduction
It remains controversial whether non-malignant 'benign' hypertension causes renal dysfunction. [1] [2] [3] [4] [5] Although elevated blood pressure predicts subsequent development of end-stage renal disease, 6, 7 it is possible that pre-existing renal disease caused both the hypertension and the eventual renal failure. 8, 9 The effect of lowering blood pressure on the incidence of renal dysfunction among patients with non-malignant hypertension is also not known. Some observational studies have shown that for hypertensive patients, treated blood pressure level did not protect against subsequent rise in serum creatinine. lowering blood pressure decreases the incidence of renal dysfunction among patients with non-malignant hypertension is a randomised controlled trial. However, renal disease has not been a major focus in the large traditional antihypertensive drug treatment trials. Furthermore, there are too few renal endpoints within any one study to provide sufficient power and to make definitive conclusions. Therefore, this meta-analysis was conducted to integrate the results of previous trials into a more precise estimate of treatment effect. Specifically, it asks whether in randomised, controlled trials, drug treatment of non-malignant hypertension reduces the incidence of renal dysfunction.
Methods

Identification of trials
Randomised controlled trials of antihypertensive drugs among patients with non-malignant hypertension were identified using prior meta-analyses, bib-
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liographies in recent articles and textbooks and MED-LINE searches. Locating relevant studies was facilitated by the fact that numerous meta-analyses of this literature have been performed that used similar trial selection criteria. [12] [13] [14] [15] [16] However, these published systematic analyses have mostly focused on cardiovascular disease outcomes. Extra effort was expended on locating recent publications and a rigorous MED-LINE search strategy designed by the Cochrane Collaboration to identify trials of pharmacological treatment of hypertension 16 was conducted for the period 1995 through 1998. A total of 2617 records were produced. The title and abstract of each record were evaluated and full text of 31 articles obtained for further evaluation. No additional trials met eligibility criteria for this review.
Inclusion criteria
Trials of randomised antihypertensive drug therapy included in the meta-analysis are those published before 1 January, 1999 that: (1) lasted over 1 year; (2) explicitly described random allocation of treatment (ie, did not use alternate allocation or other potentially biased methods); and (3) reported renal dysfunction as an outcome. Trials that compared the effects of two specific antihypertensive therapies with the same blood pressure goal were excluded. Trials of multiple risk factor interventions were excluded because of potential confounding by other therapies. Also excluded were trials that enrolled only patients with known renal insufficiency or established renal parenchymal disease [17] [18] [19] since this study was not designed to examine the effect of blood pressuring lowering in patients who already had renal dysfunction.
Extraction of data
The author used a standardised abstraction sheet to extract the following data from each study: year of publication, number of subjects, mean age, percent male, baseline systolic and diastolic blood pressures, types of medication used, blinding, use of placebo or a less intensely treated group as control, duration of follow-up, and mean difference in observed blood pressure between treatment and control groups. The proportion of black (or non-white 20 ) participants was also abstracted. This was hypothesised a priori to be a possible source of heterogeneity among studies, as black subjects are believed to be particularly susceptible to renal damage from hypertension. 21, 22 Information on whether and how patients with renal disease were excluded from entry into each trial was abstracted. Also noted was how new cases of renal dysfunction were defined in the paper presenting the main findings of each trial. In some instances, renal exclusion criteria and definition of renal dysfunction were found in earlier publications detailing the study protocol or pilot study. [23] [24] [25] [26] For example, the paper describing the main findings of the United States Public Health Service Hospitals (USPHS) study listed 'renal insufficiency' as an exclusion criterion and as a secondary outcome. 20 An earlier paper defined 'renal insufficiency' as measured creatinine clearance Ͻ80 ml/min/ 1.73m 2 .
24
In all trials, whenever possible, intention-to-treat analysis outcome data were used as input data for the meta-analysis. In the European Working Party on High Blood Pressure in the Elderly Trial (EWPHE), serial serum creatinine measurements were performed only during the randomised part of the study, but mortality and cause of death data continued to be collected on all patients after withdrawal from randomisation. 28 During randomisation, one treated patient died of renal disease and four treated and one control patients had doubling of serum creatinine. In the overall intention-to-treat analysis, four treated and one control patient died of renal disease. 28, 29 Because ascertainment of serum creatinine doubling may be more reliable than nosologist's coding of cause of death, the 'on treatment' data were used. In the Systolic Hypertension in the Elderly Program (SHEP), a rise in serum creatinine to Ͼ265 mol/l (3 mg/dl) was explicitly listed as a secondary endpoint. 30 In addition, it was reported that two patients each in the treatment and control arm died of renal disease, which was not a stated endpoint. These were therefore not counted. Performing the meta-analysis using these alternative endpoints did not significantly change the final conclusions of the study.
In two instances, after publication of the paper describing the main trial findings, secondary analyses of trial data were performed which provided more information on renal function changes.
21,31
The meta-analysis was repeated to incorporate the results of these secondary analyses.
Statistical analysis
The effect of antihypertensive medication on the development of renal dysfunction was determined in each trial using the relative risk (RR), calculated by the ratio of the incidence of renal dysfunction in the treatment vs control group. In cases where there were no events, a 1/6 arithmetic correction was added to all cells. 32 A random-effects model as described by DerSimonian and Laird was used to obtain the summary estimates of log (RR) from the included studies. 33 Effect homogeneity was evaluated by the Q-statistic. 33 Stata Release 6 (College Station, TX, USA) was used to perform the analysis and to produce graphic output (command 'meta').
Results
Ten trials were identified that met the inclusion criteria 20, 27, 28, 30, [34] [35] [36] [37] [38] [39] (Table 1) . These encompassed a total of 26 521 individuals and 114 000 person-years of observation. Eight trials were placebo-controlled and two used less-intensively treated patients as controls. 37, 38 Drug treatment consisted mostly of diuretics and adrenergic blockers. Only one trial used angiotensin-converting enzyme (ACE) inhibitors. 39 Overall, treated patients had lower blood pressure and experienced fewer cardiovascular events.
All trials excluded subjects with advanced baseline renal disease ( Table 1 ). The Hypertension Detection and Follow-up Program (HDPF) did not have any renal exclusion criteria 40 but there were no enrollees with serum creatinine (Cr) Ͼ265 mol/l (3 mg/dl). 21 Coope and Warrender 38 did not mention specific renal exclusion criteria but had a general blanket exclusion of 'serious concomitant disease'.
Definition of renal dysfunction outcome varied among trials but within each trial was applied similarly to both treatment and control groups ( Table 2) . A total of 72 cases of renal dysfunction were identified. Compared with control patients, the relative risk of developing renal dysfunction among patients
Journal of Human Hypertension randomised to antihypertensive therapy (or more intensive therapy) was 0.95 (95% confidence interval (CI) 0.58-1.55; P ϭ 0.83) (Q-statistic ϭ 8.5; P ϭ 0.48) (Figure 1) .
Secondary analyses of trial data were reported by the HDFP and the SHEP investigators that provided additional information on renal function changes. 21, 31 Using the HDFP data and redefining renal dysfunction as 5th year creatinine у180 mol/l (2 mg/dl) and у1.25 times baseline value, Shulman et al 21 found that there were a total of 200 cases of renal dysfunction. Pahor et al 31 showed that in the SHEP study, when the definition of renal dysfunction was changed from serum creatinine Ͼ265 mol/l (3 mg/dl) to serum creatinine Ͼ180 mol/l (2 mg/dl), the number of renal dysfunction cases increased from 18 to 88 31 (Table 3) . Repeating the meta-analysis with 317 outcomes after incorporating the results of the secondary analyses showed that the relative risk of developing renal dysfunction among treatment vs control patients was 0.97 (95%CI 0.78-1.21; P ϭ 0.77) OR Cr у360 mol/l (4 mg/dl) on two consecutive measurements a Cr, serum creatinine; BUN, blood urea nitrogen.
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Figure 1
Result of meta-analysis using original trial data. Graph shows estimates and 95% CI for each trial and overall effect. Box area is inversely proportional to the estimated effect's variance in that study. Vertical dotted line is drawn through combined estimate. 
Figure 2
Result of meta-analysis using secondary analyses data. Graph shows estimates and 95% CI for each trial and overall effect. Box area is inversely proportional to the estimated effect's variance in that study. Vertical dotted line is drawn through combined estimate.
( Figure 2 ). There was again failure to detect heterogeneity among the trials (Q-statistic ϭ 6.7; P ϭ 0.67); therefore the random effects model gave the fixed effects results.
Discussion
This systematic review of 10 randomised controlled trials of patients treated with antihypertensive medications found no significant reduction in the incidence of renal dysfunction among treated patients. There appeared to be no significant heterogeneity among trials as a result of enrollees' racial composition or other variables. The 95% CI suggests that at the observed level of blood pressure reduction, a 25% or more true protective effect of antihypertensive drugs is unlikely.
While it is clear that malignant hypertension damages the kidneys, whether non-malignant 'benign' hypertension causes renal dysfunction remains controversial. [1] [2] [3] [4] [5] Chronic elevations in blood pressure
Journal of Human Hypertension may lead to narrowing of renal arteriolar lumen and glomerular ischaemia; alternatively, direct transmission of elevated pressure to the glomerulus may lead to glomerulosclerosis. 41 Epidemiological study of the relationship between hypertension and renal dysfunction is difficult. Because hypertension can be a consequence of renal parenchymal disease or decreased glomerular filtration, cross-sectional and retrospective studies cannot be used to establish causal relationship between hypertension and renal dysfunction. 42 Prospective observational studies have shown that among 11 912 hypertensive male veterans and among 332 544 men screened for the Multiple Risk Factor Intervention Trial (MRFIT), elevated blood pressure measured over a decade in the past predicted subsequent risk of end-stage renal disease (ESRD). 6, 7 However, except in a small subset of the MRFIT cohort (Ͻ4%), 7 baseline renal function data were not assessed in these subjects. Hence it is not possible to discern whether renal dysfunction was
Journal of Human Hypertension already present in those in whom ESRD later developed. In a Japanese study of 107 192 subjects who had undergone screening with dipstick urinalysis and blood pressure measurement, 5% of subjects had у1+ proteinuria and 4% of men and 12% of women had у1+ hematuria. 8 A subset of 14 609 subjects had serum creatinine measured. 9 Although higher blood pressure predicted subsequent development of ESRD 10 years post-screening, this relationship was confounded by the presence of underlying renal disease. After adjusting for baseline serum creatinine, proteinuria and hematuria, elevated blood pressure was no longer an independent risk factor for ESRD. 8, 9 This supports the contention that many patients with renal failure attributed to essential hypertension actually have undiagnosed renal vascular or renal parenchymal disease 3 that caused both the initial blood pressure elevation and eventual renal failure.
Whether treatment of hypertension reduces the incidence of renal dysfunction may be a more relevant public health and clinical question than whether hypertension predicts renal dysfunction. Despite improved detection and control of high blood pressure in the US from 1977-1994, which reduced stroke and coronary disease mortality, the incidence of ESRD attributed to hypertension has increased. 43 One study of 94 patients with treated primary hypertension showed that over a mean observation period of 58 months, individuals with good blood pressure control (diastolic р90 mm Hg) developed increases in serum creatinine concentration at the same rate as those with poor blood pressure control (diastolic Ͼ90 mm Hg). 10 Similarly, among 2125 hypertensive men enrolled for treatment, changes in serum creatinine over 5 years were not predicted by in-treatment blood pressure, analysed either as a continuous or as a dichotomous variable. 11 In a subgroup analysis of 5524 MRFIT enrollees, despite a 5-mm Hg difference in diastolic blood pressure between those receiving usual care and special intervention, reciprocal creatinine slopes over 6 years in the two groups were the same. 22 Randomised controlled trials using only antihypertensive medications, however, provide the most direct and unbiased study design to address whether treatment of hypertension reduces the incidence of renal dysfunction among patients with non-malignant hypertension. Patients with diagnosed and undiagnosed renal disease should be evenly distributed in the treatment and the control group so that confounding from this important source is eliminated. The strength of the original randomisation is preserved in a meta-analysis. Although results of antihypertensive drug trials have been used to inform the debate on the relationship between hypertension and renal dysfunction in the past, 4, 44, 45 a formal meta-analysis has not been performed.
The finding that blood pressure lowering had no evident renoprotective effect should be interpreted in light of the fact that these trials did not rigorously exclude patients with reduced glomerular filtration rate or known renal parenchymal disease. The relatively high serum creatinine cutoff used in many trials (eg, Ͼ180 mol/l (2 mg/dl)) did not exclude patients with significant loss of glomerular filtration. For example, a 60-year-old woman weighing 60 kilograms with a serum creatinine of 170 mol/l (1.9 mg/dl), and therefore Cockcroft-Gault equation 46 estimated creatinine clearance of only 30 ml/min, would have been enrolled. Many studies included patients with diabetes. Among the SHEP participants, 11% reported a history of 'kidney problems'. 47 Renal parenchymal disease was considered the cause of elevated blood pressure in 8% of EWPWE subjects with systolic hypertension. 48 In the HDFP population, which included patients with known glomerulonephritis, 21 4% had у2+ proteinuria, 5% had hematuria and 7% pyuria. 49 It is generally accepted that blood pressure reduction slows renal function deterioration in patients with established renal parenchymal disease or decreased glomerular filtration rate. 50, 51 Therefore, the fact these patients were included in the trial cohorts and blood pressure lowering conferred no overall renoprotection renders it even less likely that antihypertensive medications lowered the risk of renal dysfunction among patients with only nonmalignant essential hypertension.
This study has several limitations. Bias may be introduced because a single unblinded author conducted this study. Bias in identification of trials, however, is unlikely given that these are such large and well-known undertakings. Only published data were used but publication bias is doubtful as trials that fulfill the selection criteria for this meta-analysis would almost certainly be published, regardless of the renal outcomes. Furthermore, since trials with 'positive findings' tend to be published, the 'null result' of this meta-analysis is highly unlikely to be a result of publication bias.
The two studies that provided the largest number of end-points are both secondary analyses using renal outcome criteria not defined in the original protocol. The SHEP secondary analysis only included 92% of the cohort who had a valid measurement of serum creatinine by the day of randomisation. 31 In HDFP, because of its unblinded design, follow-up serum creatinine ascertainments were more complete in the treatment group (90% vs 83%). 21 However, the similar relative risks obtained from analysing the original and the secondary analyses data argue against significant bias in this case.
The 10 trials differed in their definition of renal dysfunction and included patients with varying degrees of blood pressure elevation. Direct comparison, however, was made only between treatment and control patients in the same trial. The inclusion of studies with very small numbers of events (eg, the EWPHE, the Coope, and the two VA trials), resulted in a broad spread of risk estimates with very wide confidence intervals. In actuality, there was no between trial heterogeneity beyond that expected due to chance (Q-statistic ϭ 6.7; P ϭ 0.67).
This study does not address how stricter or longer-term control of blood pressure will impact the incidence of renal dysfunction. The longest follow-up was 7 years for the USPHS trial and most of the other studies lasted 4 to 5 years. It is not clear how low the blood pressure has to be or how long the subjects have to be followed for the renoprotective effect of antihypertensive drug therapy to become apparent in patients with non-malignant hypertension, if such an effect truly exists.
This study is unable to evaluate the effects of newer classes of antihypertensive medications, such as ACE inhibitors or angiotensin receptor antagonists. Experimental studies 52 and clinical trials 51, 53 in a variety of primary renal diseases with hypertension suggest that agents which specifically reduce intraglomerular pressure, in addition to systemic arterial pressure, attenuation loss of renal function over time. Whether these findings would translate into a worthwhile clinical benefit in patients with non-malignant essential hypertension is unknown.
Despite these shortcomings, this meta-analysis represents the best unconfounded estimate that can be derived from the present medical literature of the effect of non-malignant hypertension treatment on risk of subsequent renal dysfunction. It is doubtful that an actual trial designed specifically to examine the renoprotective effect of antihypertensive drug therapy involving 27 000 individuals and 114 000 person-years of observation will ever to be conducted. The relatively low disease incidence and the proven treatment benefits in terms of strokes and other more common cardiovascular outcomes alone will make such a study logistically and ethically problematic. Hence, meta-analyses such as this one may be the best approximation of a randomised controlled trial in this field.
The results of this meta-analysis obviously should not be used to argue against treating patients with non-malignant hypertension, since there are clear non-renal benefits. Nor should they diminish our enthusiasm for controlling hypertension in patients with primary renal disease, particularly those with proteinuria, where hypertension control has clearly been shown to attenuate the rate of progression to end-stage renal disease. 54 , 55 The results of this metaanalysis however should encourage rethinking of whether non-malignant hypertension by itself is an important cause of renal dysfunction since the current best available data from randomised clinical trials fail to show that antihypertensive drug therapy reduces the incidence of renal dysfunction in patients with non-malignant hypertension.
